Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

M-AMOXI CLAV 400 MG / 5 ML

AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 400 MG / 5 ML CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 57 MG / 5 ML · DIN 02530694 · MANTRA PHARMA INC

Health Canada status: MARKETED

What is M-AMOXI CLAV?

M-AMOXI CLAV 400 MG / 5 ML contains AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 400 MG / 5 ML CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 57 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02530694, held by MANTRA PHARMA INC, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Nov-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is M-AMOXI CLAV used for?

M - AMOXI CLAV is indicated for the treatment of sinusitis, otitis media, lower respiratory tract infections, skin and soft tissue infections, and urinary tract infections when caused by M - AMOXI CLAV-susceptible strains of designated bacteria. Infections caused by ampicillin (amoxicillin) susceptible organisms are also amenable to M - AMOXI CLAV treatment. Mixed infections caused by organisms susceptible to ampicillin (amoxicillin) and β - lactamase producing organisms susceptible to M - AMOXI CLAV should not require the addition of another antibiotic.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02530694
Brand nameM-AMOXI CLAV
Generic / active ingredientAMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 400 MG / 5 ML CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 57 MG / 5 ML
ManufacturerMANTRA PHARMA INC
Strength400 MG / 5 ML
Dosage formPOWDER FOR SUSPENSION
Route of administrationORAL
SchedulePrescription
ATC codeJ01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR
AHFS class08:12.16.08
BiosimilarNo
Health Canada statusMARKETED
Status date24-Nov-2022
Original market date2022-11-24 00:00:00

How is it stored and handled?

The reconstituted M - AMOXI CLAV (250 mg / 62.5 mg per 5 mL) oral suspension should be stored under refrigeration (2°C to 8°C) and should be used within 10 days. The reconstituted M - AMOXI CLAV (400 mg / 57 mg per 5 mL) oral suspension should be stored under refrigeration (2°C to 8°C) and should be used within 7 days.

How is it supplied?

M - AMOXI CLAV (250 mg / 62.5 mg) is available in bottles of 100 mL (reconstitution volume). M - AMOXI CLAV (400 mg / 57 mg) is available in bottles of 70 mL (reconstitution volume).

Is AMOXICILLIN AND BETA-LACTAMASE INHIBITOR in shortage in Canada?

A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for M-AMOXI CLAV

What can be used instead?

Other Canadian products sharing ATC code J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR. 28 of 59 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
AG-AMOXI CLAV500 MGTABLETANGITA PHARMA INC.MARKETEDDIN 02510634
AG-AMOXI CLAV875 MGTABLETANGITA PHARMA INC.MARKETEDDIN 02510642
AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION100 MGPOWDER FOR SOLUTIONSANDOZ CANADA INCORPORATEDMARKETEDDIN 02495910
AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION1000 MGPOWDER FOR SOLUTIONSANDOZ CANADA INCORPORATEDMARKETEDDIN 02495929
AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION2000 MGPOWDER FOR SOLUTIONSANDOZ CANADA INCORPORATEDMARKETEDDIN 02495937
AMOXICILLIN/CLAV500 MGTABLETSANIS HEALTH INCMARKETEDDIN 02536021
AMOXICILLIN/CLAV875 MGTABLETSANIS HEALTH INCMARKETEDDIN 02536048
APO-AMOXI CLAV125 MGTABLETAPOTEX INCMARKETEDDIN 02243350
APO-AMOXI CLAV500 MGTABLETAPOTEX INCMARKETEDDIN 02243351
APO-AMOXI CLAV875 MGTABLETAPOTEX INCMARKETEDDIN 02245623

Who else supplies AMOXICILLIN AND BETA-LACTAMASE INHIBITOR worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR appears in 3391 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for M-AMOXI CLAV

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for M-AMOXI CLAV

Health Canada Drug Product Database (DPD), DIN 02530694. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.